Search results
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool via Yahoo Finance· 4 months agoEditas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few...
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 weeks agoEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript May 8, 2024 Editas Medicine,...
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
Simply Wall St. via Yahoo Finance· 2 weeks agoKey Insights Significantly high institutional ownership implies Editas Medicine's stock price is...
Is Editas Medicine Stock a Buy Now?
Motley Fool· 11 months agoInvestors tend to move away from somewhat speculative stocks when the economic going gets rough. Editas Medicine's most advanced candidate is EDIT-301,...
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
Motley Fool via Yahoo Finance· 4 months agoInvesting in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but...
Where Will Editas Medicine Be in 1 Year?
Motley Fool· 1 year agoGene-editing specialist Editas Medicine (NASDAQ: EDIT) fits the bill, which is why the company's shares have plunged this year. Could this be what's in...
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest...
Simply Wall St. via Yahoo Finance· 1 week agoEditas Medicine, Inc. (NASDAQ:EDIT) just released its latest quarterly report and things are not...
Will Editas Medicine (NASDAQ:EDIT) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 2 years agoJust because a business does not make any money, does not mean that the stock will go down. For...
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
Motley Fool· 1 year agoEditas Medicine (NASDAQ: EDIT) sits at the bleeding edge of biotech's hottest field, gene editing to...
Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ...
GuruFocus.com via Yahoo Finance· 7 months agoEditas Medicine Inc (NASDAQ:EDIT) reports a net loss of $45.0 million for Q3 2023, down from $55.7...